copyrightwmichaelscheld,md内容摘要：
NDA Pipeline。 “pink sheet”) ABT773 Afelimomab Tigecycline (vs 18 novel oncology agents) 12 IOM report, 2020 “Unfortunately, placency toward infections diseases in the 1960’s, overconfidence in existing antibiotics, and petition from highly profitable opportunities for pharmaceutical development and sale in other fields of medicine resulted in a lag in the production of new classes of antibodies. This occurred despite significant advances in the fundamental science that has fueled pharmaceutical innovation in many other areas” 13 IDSA Antimicrobial Availability Task Force Charge “Develop novel public policy to ensure a sustainable supply of safe and effective antimicrobial drugs to protect public health” 14 TASK FORCE MEMBERS John G. Bartlett, MD, Chair John Hopkins Univ. SOM Baltimore, MD。阅读剩余 0%
本站所有文章资讯、展示的图片素材等内容均为注册用户上传(部分报媒/平媒内容转载自网络合作媒体)，仅供学习参考。
用户通过本站上传、发布的任何内容的知识产权归属用户或原始著作权人所有。如有侵犯您的版权，请联系我们反馈本站将在三个工作日内改正。